According to results released by Living Cell Technologies Limited, diabetes patients that received implants of DiabeCell (R) encapsulated porcine islet cells for type 1 diabetics have reported positive results.
Six patients have now been given the treatment, which involved 5,000 islet implants. No adverse affects have yet been reported, allowing the company to do a 12 month follow up trial .
The medical director of LCT, Professor Elliott, reportedly commented: “At this stage in the DiabeCell(R) trial clinical benefit has been observed in all five patients receiving the lowest dose which has far exceeded our expectations. In the first group, following DiabeCell(R) implants we have seen reductions in daily insulin requirements ranging from 23% to as much as 100% while maintaining good control of blood glucose levels in four out of five patients.”
The trial is underway in Moscow.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…